Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 6/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081014 | 0.80 | TOP2A (0.56) | CHRM1KDM4EKMT2AKCNH2MEN1 | |
| SCHEMBL2082061 | 0.78 | CYP3A4 (0.51) | KDM4EKMT2AKCNH2LMNATOP2A | |
| SCHEMBL27511886 | 0.78 | CYP3A4 (0.51) | KDM4EKMT2AKCNH2LMNATOP2A | |
| SCHEMBL2082062 | 0.78 | CYP3A4 (0.51) | KDM4EKMT2AKCNH2LMNATOP2A | |
| SCHEMBL4208120 | 0.77 | TOP2A (0.53) | CHRM1KDM4EKMT2AKCNH2MEN1 | |
| SCHEMBL9148710 | 0.76 | LMNA (0.55) | CHRM1KDM4EKMT2AMEN1ABCC4 | |
| SCHEMBL30417633 | 0.74 | CHRM1 (0.50) | CHRM1KDM4EKMT2ALMNATOP2A | |
| SCHEMBL6662423 | 0.73 | ALDH1A1 (0.43) | KDM4EKMT2AMEN1LMNATOP2A | |
| SCHEMBL7471382 | 0.72 | TOP2A (0.44) | KCNH2TOP2ATOP2BPOLB | |
| SCHEMBL4677281 | 0.71 | KCNH2 (0.49) | CHRM1KDM4EKMT2AKCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882689-B1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8211910-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| EP-2463274-A1 | Tri-or tetra-substituted-3-aminopyrrolidine deritatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7563805-B2 | 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| EP-1882689-A1 | TRI- OR TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2008-01-30 | — | — | EP | disclosed |
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264428-A1 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | QTRT1, RRS1, LAS1L | CHRM1 677/4885KDM4E 2926/4885KMT2A 2638/4885 |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | AAAS, NPEPPS, TEAD4 | CHRM1 4751/4885KDM4E 3137/4885KMT2A 3317/4885 |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | CHRM1 4749/4885KDM4E 2911/4885KMT2A 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.